selenomethylselenocysteine has been researched along with Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S | 1 |
| Bergan, R; Burk, RF; Davis, W; George, S; Hill, KE; Marshall, JR; Payne Ondracek, R; Perloff, M; Pili, R | 1 |
| Aitken, JB; Finney, L; Harris, HH; Vogt, S; Weekley, CM; Witting, PK | 1 |
| Harris, HH; Weekley, CM | 1 |
| Cao, S; Durrani, FA; Rustum, YM; Tóth, K | 1 |
| Gangapurkar, B; Jariwalla, RJ; Nakamura, D | 1 |
| Echigo, S; Endo, M; Rikiishi, H; Shinohara, F; Suzuki, M | 1 |
| Cheng, WH; Kang, MM; Schoene, NW; Wu, M | 1 |
| Aitken, JB; de Jonge, MD; Finney, LA; Harris, HH; Howard, DL; Musgrave, IF; Paterson, DJ; Vogt, S; Weekley, CM | 1 |
| Bhattacharya, A | 1 |
| Bernhard, EJ | 1 |
| Antoch, MP; Chernov, MV; Comas-Soberats, M; Fedtsova, N; Gleiberman, AS; Gudkov, AV; Hu, Y; Jackson, M; Kuropatwinski, KK; Rustum, YM; Spengler, ML | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Cao, S; Durrani, FA; Fakih, M; Rustum, YM | 1 |
| Abdulah, R; Koyama, H; Miyazaki, K; Nakazawa, M | 1 |
| Azrak, RG; Cao, S; Combs, GF; Durrani, FA; Fakih, M; Pendyala, L; Prey, J; Rustum, YM; Smith, PF | 1 |
6 review(s) available for selenomethylselenocysteine and Neoplasms
| Article | Year |
|---|---|
Selenium metabolism in cancer cells: the combined application of XAS and XFM techniques to the problem of selenium speciation in biological systems.
Topics: Animals; Copper; Fluorescence; Humans; Microscopy, Fluorescence; Neoplasms; Organoselenium Compounds; Selenium; Selenocysteine; Selenomethionine; Sodium Selenite; X-Ray Absorption Spectroscopy | 2013 |
Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease.
Topics: Clinical Trials as Topic; Cystine; Dietary Supplements; Histone Deacetylase Inhibitors; Humans; Neoplasms; Organoselenium Compounds; Reactive Oxygen Species; Selenium Compounds; Selenocysteine; Selenomethionine; Selenoproteins; Sulfhydryl Compounds | 2013 |
Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cysteine; Drug Synergism; Humans; Neoplasms; Organoselenium Compounds; Selenocysteine | 2011 |
Interventions that induce modifications in the tumor microenvironment.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Adhesion; Cell Hypoxia; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cysteine; Cytotoxins; Drug Screening Assays, Antitumor; Extracellular Matrix; Genetic Therapy; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Neoplastic Stem Cells; Neovascularization, Pathologic; Organoselenium Compounds; Radiation Tolerance; Radiotherapy; Selenocysteine; Signal Transduction; Stromal Cells; Tumor Microenvironment | 2011 |
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine; Drug Synergism; Humans; Irinotecan; Mice; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Selenomethionine | 2005 |
Chemical forms of selenium for cancer prevention.
Topics: Anticarcinogenic Agents; Chromatography; Chromatography, High Pressure Liquid; Cysteine; Food; Glutathione Peroxidase; Humans; Iodide Peroxidase; Mass Spectrometry; Methionine Sulfoxide Reductases; Models, Chemical; Neoplasms; Organoselenium Compounds; Selenium; Selenocysteine; Selenoprotein P; Selenoprotein W; Thioredoxin-Disulfide Reductase | 2005 |
1 trial(s) available for selenomethylselenocysteine and Neoplasms
| Article | Year |
|---|---|
Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.
Topics: Adult; Aged; Case-Control Studies; Chemoprevention; Dietary Supplements; Drug Monitoring; Humans; Male; Middle Aged; Neoplasms; Selenocysteine; Selenomethionine; Time Factors | 2017 |
9 other study(ies) available for selenomethylselenocysteine and Neoplasms
| Article | Year |
|---|---|
Combination of Se-methylselenocysteine, D-α-tocopheryl succinate, β-carotene, and L-lysine can prevent cancer metastases using as an adjuvant therapy.
Topics: alpha-Tocopherol; Animals; Antioxidants; Apoptosis; beta Carotene; Cell Line, Tumor; Cell Proliferation; Lysine; Mice; Neoplasms; Paclitaxel; Quality of Life; Succinates | 2022 |
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cytoprotection; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Rats; Rats, Inbred F344; Selenocysteine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Differential sensitivity of various human tumour-derived cell types to apoptosis by organic derivatives of selenium.
Topics: Adenocarcinoma; Adolescent; Adult; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cysteine; Epithelial Cells; Female; Humans; Liver Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Organoselenium Compounds; Selenium Compounds; Selenocysteine; Selenomethionine; Skin Neoplasms | 2009 |
Differential apoptotic response of human cancer cells to organoselenium compounds.
Topics: Anticarcinogenic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cysteine; Flow Cytometry; Humans; Neoplasms; Organoselenium Compounds; Selenocysteine; Selenomethionine; Sodium Selenite; Tumor Suppressor Protein p53 | 2010 |
Selenium compounds activate early barriers of tumorigenesis.
Topics: Anticarcinogenic Agents; Antioxidants; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cellular Senescence; Cysteine; DNA Damage; DNA Repair; DNA-Binding Proteins; Histones; Humans; Male; Neoplasms; Organoselenium Compounds; Oxidative Stress; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Selenium Compounds; Selenocysteine; Sodium Selenite; Tumor Suppressor Proteins | 2010 |
Uptake, distribution, and speciation of selenoamino acids by human cancer cells: X-ray absorption and fluorescence methods.
Topics: Cell Line, Tumor; Cysteine; Humans; Microscopy, Fluorescence; Neoplasms; Organoselenium Compounds; Selenocysteine; Selenomethionine; X-Ray Absorption Spectroscopy | 2011 |
Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1.
Topics: Animals; ARNTL Transcription Factors; Cell Line, Tumor; Circadian Clocks; CLOCK Proteins; Cyclophosphamide; Cysteine; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Neoplasms; Organoselenium Compounds; Period Circadian Proteins; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Selenium Compounds; Selenocysteine; Transcription Factors; Transcription, Genetic; Transcriptional Activation | 2011 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Topics: Administration, Oral; Animals; Bone Marrow; Camptothecin; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Kidney; Kinetics; Liver; Mice; Mice, Nude; Neoplasms; Organoselenium Compounds; Plasma; Selenium; Selenocysteine | 2007 |